Company Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders.
The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia.
Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jul 1, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Remy Luthringer |
Contact Details
Address: 1500 District Avenue Burlington, Massachusetts 01803 United States | |
| Phone | 617 600 7373 |
| Website | minervaneurosciences.com |
Stock Details
| Ticker Symbol | NERV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001598646 |
| CUSIP Number | 603380205 |
| ISIN Number | US6033802058 |
| Employer ID | 26-0784194 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Remy Luthringer Ph.D. | Executive Chairman and Chief Executive Officer |
| Geoffrey Robin Race F.C.M.A., M.B.A. | President |
| Frederick W. Ahlholm CPA | Senior Vice President, Chief Financial Officer and Secretary |
| Joseph Reilly | Senior Vice President and Chief Operating Officer |
| William B. Boni | Vice President of Investor Relations and Corporate Communications |
| Prof. Michael Davidson M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Oct 22, 2024 | ARS | Filing |
| Oct 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 22, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 11, 2024 | 8-K | Current Report |
| Sep 16, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| May 30, 2024 | 8-K | Current Report |